Akebia Therapeutics (AKBA) Depreciation & Amortization - Total (2019 - 2026)
Akebia Therapeutics (AKBA) reported Depreciation & Amortization - Total of $328000.0 for Q1 2026, up 4.46% year-over-year from $314000.0 in Q1 2025, and up 2.18% quarter-over-quarter from $321000.0 in Q4 2025.
Akebia Therapeutics (AKBA) Depreciation & Amortization - Total (2019 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has 7 years of Depreciation & Amortization - Total data on file, last reported at $328000.0 in Q1 2026.
- Depreciation & Amortization - Total for Q1 2026 came in at $328000.0, up 4.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (down 9.14% YoY), and the FY2025 annual result was $1.3 million, down 13.2% from the prior year.
- Depreciation & Amortization - Total rose to $328000.0 in Q1 2026 per AKBA's latest filing, from $321000.0 in the prior quarter.
- Over five years, Depreciation & Amortization - Total peaked at $408000.0 in Q4 2022 and troughed at $314000.0 in Q1 2025.
- A 5-year average of $360857.1 and a median of $363500.0 in 2024 frame the typical range for Depreciation & Amortization - Total.
- The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization - Total fell 21.0% in 2025, then climbed 4.46% in 2026.
- A 5-year view of Depreciation & Amortization - Total shows it stood at $408000.0 in 2022, then dropped by 3.43% to $394000.0 in 2023, then slipped by 14.97% to $335000.0 in 2024, then dropped by 4.18% to $321000.0 in 2025, then increased by 2.18% to $328000.0 in 2026.
- Business Quant data shows AKBA's Depreciation & Amortization - Total at $328000.0 in Q1 2026, $321000.0 in Q4 2025, and $318000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Tot) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.97 Bn | 36.23 Bn | 1.97 Bn | - |
| 2 | Zoetis | 33.59 Bn | 31.65 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | - |
| 4 | Neurocrine Biosciences | 16.10 Bn | 14.78 Bn | 800.70 Mn | - |
| 5 | Aurora Cannabis | 15.56 Bn | 15.47 Bn | 21.72 Mn | - |
| 6 | Elanco Animal Health | 12.04 Bn | 11.61 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.36 Bn | 6.84 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.74 Bn | 6.24 Bn | 230.92 Mn | - |
| 9 | Liquidia | 6.27 Bn | 6.04 Bn | 121.79 Mn | - |
| 10 | Akebia Therapeutics | 245.66 Mn | 83.06 Mn | 41.25 Mn | 328,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 328,000.00 |
| Dec 31, 2025 | 321,000.00 |
| Sep 30, 2025 | 318,000.00 |
| Jun 30, 2025 | 316,000.00 |
| Mar 31, 2025 | 314,000.00 |
| Dec 31, 2024 | 335,000.00 |
| Sep 30, 2024 | 363,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 364,000.00 |
| Dec 31, 2023 | 394,000.00 |
| Sep 30, 2023 | 396,000.00 |
| Jun 30, 2023 | 397,000.00 |
| Mar 31, 2023 | 398,000.00 |
| Dec 31, 2022 | 408,000.00 |
| Dec 31, 2020 | 500,000.00 |
| Sep 30, 2020 | 500,000.00 |
| Jun 30, 2020 | 500,000.00 |
| Dec 31, 2019 | 500,000.00 |
| Sep 30, 2019 | 600,000.00 |
| Jun 30, 2019 | 600,000.00 |